Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Regeneron Pharma | Vienna | Healthcare | Biotechnology & Medical Research | €51.37B | 13x | 0.86 | €477 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Regeneron Pharmaceuticals | Milan | Healthcare | Biotechnology & Medical Research | €51.37B | 13x | 0.86 | €480.50 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Regeneron Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | €50.47B | 12.9x | 0.86 | €490.50 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Lonza Group | BATS Europe | Healthcare | Biotechnology & Medical Research | €44.18B | 58x | €625.22 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
argenx | Frankfurt | Healthcare | Biotechnology & Medical Research | €30.26B | 31.7x | 0.14 | €485 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
arGEN X BV | BATS Europe | Healthcare | Biotechnology & Medical Research | €30.26B | 31.7x | 0.15 | €548.60 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Argen-X | Brussels | Healthcare | Biotechnology & Medical Research | €30.26B | 31.7x | 0.14 | €496 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 43.7% Upside | Upgrade to Pro+ | |
argenx SE | Vienna | Healthcare | Biotechnology & Medical Research | €30.26B | 31.7x | 0.14 | €500.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
IQVIA Holdings | Vienna | Healthcare | Biotechnology & Medical Research | €23.16B | 20.5x | 7.18 | €136.40 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE DRC | Vienna | Healthcare | Biotechnology & Medical Research | €20.03B | -26.1x | 0.19 | €83.55 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE | Xetra | Healthcare | Biotechnology & Medical Research | €19.99B | -26.1x | 0.19 | €83.35 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biontech | Frankfurt | Healthcare | Biotechnology & Medical Research | €19.97B | -26.1x | 0.19 | €83.10 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab AS | Vienna | Healthcare | Biotechnology & Medical Research | €11B | 10.6x | 0.13 | €174.75 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab | BATS Europe | Healthcare | Biotechnology & Medical Research | €10.99B | 10.6x | 0.14 | €174.20 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eurofins Scientific | BATS Europe | Healthcare | Biotechnology & Medical Research | €10.84B | 0.7 | €56.12 | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Eurofins Scientific | Paris | Healthcare | Biotechnology & Medical Research | €10.84B | 33.3x | 0.71 | €56.34 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2.5% Downside | Upgrade to Pro+ | |
Eurofins Scientific SE | Vienna | Healthcare | Biotechnology & Medical Research | €10.84B | 33.3x | 0.71 | €56.42 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eurofins Scientific | Frankfurt | Healthcare | Biotechnology & Medical Research | €10.84B | 33.3x | 0.71 | €55.80 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Exelixis | Frankfurt | Healthcare | Biotechnology & Medical Research | €8.91B | 20.2x | 0.13 | €32.19 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascendis Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | €8.54B | -26.1x | -0.78 | €141 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Xetra | Healthcare | Biotechnology & Medical Research | €8.49B | -2.8x | -0.07 | €22.09 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Frankfurt | Healthcare | Biotechnology & Medical Research | €8.48B | -2.8x | -0.07 | €21.45 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Milan | Healthcare | Biotechnology & Medical Research | €8.48B | -2.8x | -0.07 | €22.03 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Vienna | Healthcare | Biotechnology & Medical Research | €8.48B | -2.8x | -0.07 | €22.17 | 3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | Frankfurt | Healthcare | Biotechnology & Medical Research | €8.11B | 97.1x | -1.47 | €37.17 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.5% Upside | Upgrade to Pro+ | |
Qiagen NV | BATS Europe | Healthcare | Biotechnology & Medical Research | €8.11B | 97.1x | -1.46 | €38.21 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | Milan | Healthcare | Biotechnology & Medical Research | €8.11B | 97.1x | -1.47 | €37.82 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen | Vienna | Healthcare | Biotechnology & Medical Research | €8.11B | 97.1x | -1.47 | €37.78 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen | Xetra | Healthcare | Biotechnology & Medical Research | €8.10B | 97.1x | -1.47 | €37.56 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.1% Upside | Upgrade to Pro+ | |
Blueprint Medicines | Frankfurt | Healthcare | Biotechnology & Medical Research | €5.67B | -40.3x | -0.9 | €88 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ionis Pharmaceuticals | Frankfurt | Healthcare | Biotechnology & Medical Research | €4.59B | -10.9x | 0.94 | €28.96 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merus NV | Frankfurt | Healthcare | Biotechnology & Medical Research | €2.55B | -10x | 1.21 | €35.80 | 7.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Denali Therapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.87B | -5.4x | 0.04 | €12.77 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech | Xetra | Healthcare | Biotechnology & Medical Research | €1.69B | -3.7x | 0.02 | €31.05 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.69B | -3.7x | 0.02 | €30.90 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech AG BATS | BATS Europe | Healthcare | Biotechnology & Medical Research | €1.69B | -3.7x | 0.02 | €31 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genus | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.63B | -353.3x | 2.94 | €24.20 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genus | BATS Europe | Healthcare | Biotechnology & Medical Research | €1.63B | -353.3x | 2.93 | €24.89 | 2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Galapagos | BATS Europe | Healthcare | Biotechnology & Medical Research | €1.50B | -8.4x | 0.06 | €22.39 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Galapagos | Amsterdam | Healthcare | Biotechnology & Medical Research | €1.50B | -8.4x | 0.06 | €22.72 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47.4% Upside | Upgrade to Pro+ | |
Galapagos NV | Vienna | Healthcare | Biotechnology & Medical Research | €1.50B | -8.4x | 0.06 | €22.82 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec | Vienna | Healthcare | Biotechnology & Medical Research | €1.34B | -6.5x | 0.05 | €7.58 | 7.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.34B | -6.5x | 0.05 | €7.58 | 9.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec AG | BATS Europe | Healthcare | Biotechnology & Medical Research | €1.34B | -6.5x | 0.06 | €7.58 | 7.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec AG | Xetra | Healthcare | Biotechnology & Medical Research | €1.34B | -6.5x | 0.05 | €7.65 | 11.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec SE | Milan | Healthcare | Biotechnology & Medical Research | €1.34B | -6.5x | 0.05 | €7.75 | 12.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Viridian Therapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | €910.33M | -3.8x | -0.25 | €11.19 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Philogen SpA | Milan | Healthcare | Biotechnology & Medical Research | €878.31M | €21.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.7% Upside | Upgrade to Pro+ | |||
Novavax | Vienna | Healthcare | Biotechnology & Medical Research | €867.81M | 2x | -0.07 | €6.19 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novavax | Frankfurt | Healthcare | Biotechnology & Medical Research | €857.29M | 2x | -0.07 | €5.38 | -9.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |